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Abstract
Background:  The introduction of pneumococcal conjugate vaccine (PCV) to the U.S.
recommended childhood immunization schedule in the year 2000 added three injections to the
number of vaccinations a child is expected to receive during the first year of life. Surveys have
suggested that the addition of PCV has led some immunization providers to move other routine
childhood vaccinations to later ages, which could increase the possibility of missing these vaccines.
The purpose of this study was to evaluate whether introduction of PCV affected immunization
coverage for recommended childhood vaccinations among 13-month olds in four large provider
groups.
Methods: In this retrospective cohort study, we analyzed computerized data on vaccinations for
33,319 children in four large provider groups before and after the introduction of PCV. The
primary outcome was whether the child was up to date for all non-PCV recommended vaccinations
at 13 months of age. Logistic regression was used to evaluate the association between PCV
introduction and the primary outcome. The secondary outcome was the number of days spent
underimmunized by 13 months. The association between PCV introduction and the secondary
outcome was evaluated using a two-part modelling approach using logistic and negative binomial
regression.
Results: Overall, 93% of children were up-to-date at 13 months, and 70% received all non-PCV
vaccinations without any delay. Among the entire study population, immunization coverage was
maintained or slightly increased from the pre-PCV to post-PCV periods. After multivariate
adjustment, children born after PCV entered routine use were less likely to be up-to-date at 13
months in one provider group (Group C: OR = 0.5; 95% CI: 0.3 – 0.8) and were less likely to have
received all vaccine doses without any delay in two Groups (Group B: OR = 0.4, 95% CI: 0.3 – 0.6;
Group C: OR = 0.5, 95% CI: 0.4 – 0.7). This represented 3% fewer children in Group C who were
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up-to-date and 14% (Group C) to 16% (Group B) fewer children who spent no time
underimmunized at 13 months after PCV entered routine use compared to the pre-PCV baseline.
Some disruptions in immunization delivery were also observed concurrent with temporary
recommendations to suspend the birth dose of hepatitis B vaccine, preceding the introduction of
PCV.
Conclusion:  These findings suggest that the introduction of PCV did not harm overall
immunization coverage rates in populations with good access to primary care. However, we did
observe some disruptions in the timely delivery of other vaccines coincident with the introduction
of PCV and the suspension of the birth dose of hepatitis B vaccine. This study highlights the need
for continued vigilance in coming years as the U.S. introduces new childhood vaccines and policies
that may change the timing of existing vaccines.
Background
The addition of pneumococcal conjugate vaccine (PCV)
to the U.S. recommended childhood immunization
schedule in the year 2000 added three injections to the
number of shots a child is expected to receive during the
first year of life. Whereas seven to ten injections were rec-
ommended during the first year of life prior to introduc-
tion of PCV, between ten and thirteen injections are now
recommended, depending on use of combination vac-
cines. With the addition of pneumococcal vaccination,
the youngest children may receive up to five injections at
a single office visit[1].
Simultaneous administration of vaccines is recommended
to facilitate early protection against vaccine-preventable
disease[2]. At the same time, administration of multiple
injections may create distress for children and parents,
and many parents and providers have previously
expressed concern regarding the administration of four
vaccines at a single visit [3-5]. It is unclear how increased
crowding of the childhood immunization schedule and
safety concerns about multiple injections related to the
introduction of PCV have affected immunization delivery.
Two regional provider surveys suggested that physicians
who administer PCV may delay other vaccinations,[4,6]
although a different, national survey found that most phy-
sicians who adopted PCV in their practices would admin-
ister four or more injections at the 2-month visit[7]. The
objective of this study was to evaluate whether the intro-
duction of PCV affected immunization delivery in actual
practice among large populations of children in several
provider groups.
Methods
Study population
This study included children enrolled in four large pro-
vider groups: Harvard Vanguard Medical Associates (Bos-
ton, MA), HealthPartners (Minneapolis, MN), Kaiser
Permanente of Colorado (Denver, CO), and Kaiser Per-
manente Northwest (Portland, OR). These sites partici-
pate in the Centers for Disease Control and Prevention
Vaccine Safety Datalink Project, in which individual-level
vaccination, demographic, and medical data are shared to
facilitate vaccine safety and other vaccine-related epidemi-
ologic research[8].
We studied infants who were born into one of the four
provider groups between October 1996 and November
2000 and had received at least one polio vaccination,
where receipt of polio vaccination was used as an indica-
tor that a child received immunizations that were
recorded by the provider group information systems (n =
86,561). To ensure that the most complete immunization
information was available, the study population was
additionally restricted to children continuously enrolled
throughout their first year of life (n = 38,588). The study
protocol was approved by the institutional review boards
at the four participating sites and the Centers for Disease
Control and Prevention.
Definition of Post-PCV and Pre-PCV exposure cohorts
Each child was assigned to one of two birth cohorts based
on the timing of their birth relative to the regulatory
approval of PCV in February 2000[9]. Individuals who
were born between October 1996 and January 2000 were
assigned to the "pre-PCV" birth cohort. Children born
between February and November 2000 were assigned to
the "post-PCV" birth cohort.
While introduction of PCV added three new vaccine injec-
tions, use of the hepatitis B-Haemophilus influenzae type B
(Hib) combination vaccine can offset the increase in vac-
cine injections a child requires to be fully immunized dur-
ing the first year of life. Hepatitis B-Hib combination
vaccine was available throughout the study period in one
provider group and was implemented in two other pro-
vider groups during the study period; in the fourth pro-
vider group, it was not available at all. Table 1 describes
how the expected number of injections varied based on
provider group-specific availability of the hepatitis B-Hib
combination vaccine during the pre-PCV and the post-
PCV periods.BMC Pediatrics 2005, 5:43 http://www.biomedcentral.com/1471-2431/5/43
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Definition of immunization coverage measures
We assessed the impact of the introduction of PCV on two
measures of immunization coverage at 13 months of age:
(1) up-to-date status and (2) time spent underimmu-
nized[10].
Vaccination histories were identified using the immuniza-
tions databases for each provider group. When vaccine
entries of the same type were recorded within seven days
of one another, the later entry was assumed to represent a
duplicate record and was excluded (0.006% – 0.56%, by
vaccine type). In addition, vaccinations that were admin-
istered before the minimum recommended age or earlier
than the minimum recommended between-vaccination
interval, allowing for a four-day grace period,[1,2] were
considered to be invalid. Only the remaining vaccinations
for eligible individuals were included in our analyses.
In general, a child was considered to be up-to-date for
non-PCV recommended vaccinations at 13 months of age
if they received all of the following: 3 diphtheria and teta-
nus toxoids and acellular or whole cell pertussis (DTP)
vaccinations; 2 polio vaccinations; 2 hepatitis B vaccina-
tions; and 3 Hib vaccinations. Children who received the
hepatitis B-Hib combination vaccine were considered up-
to-date for the hepatitis B and Hib vaccinations if they
received 2 hepatitis B vaccine doses and 2 Hib vaccine
doses by age 13 months.
The up-to-date measure includes only those vaccine doses
with recommended age ranges contained wholly included
within the 13-month individual follow-up period. Doses
with recommended age ranges that spanned the 13-
month birthday (e.g., third dose of hepatitis B vaccine rec-
ommended between 6 and 18 months of age) were not
included because children who had not yet received these
doses by age 13 months would not be considered late. As
a result, the up-to-date definition corresponds to vaccina-
tions recommended between birth and 6 months of age.
PCV was not included in the outcome definition because
the primary study objective was to evaluate whether addi-
tion of PCV affected adherence to existing vaccine recom-
mendations.
The secondary outcome, time spent underimmunized,
was defined as the number of days a child spent underim-
munized for at least one non-PCV recommended vaccina-
tion by 13 months of age and is the complement of a
previously documented outcome measure, cumulative
time spent up-to-date[11]. Because it measures the
amount of vaccination delay rather than immunization
status at a single point in time, this outcome is expected to
be more sensitive than up-to-date status at 13 months.
Operationally, we calculated time spent underimmunized
for each individual by assessing the child's up-to-date sta-
tus for the non-PCV recommended vaccinations on each
day from birth up to their 13-month birthday based on
the U.S. recommended childhood immunization sched-
ule[1]. We then summed the number of days on which the
child was not up-to-date for at least one non-PCV recom-
mended vaccination. When the recommended age range
was specified in months, a vaccination was considered
age-appropriate if it was given prior to the end of the max-
imum recommended month, where 30.5 days repre-
sented one month. Days spent underimmunized began to
accumulate following the end of this 30.5-day grace
period. For example, the first dose of diphtheria and teta-
nus toxoids and acellular pertussis combination vaccine
(DTaP) is recommended at 2 months. A child who
receives a valid DTaP by 91 days of age (i.e., (2 months*
30.5) + 30.5 day grace period = 91.5 days) is considered
to have been vaccinated age-appropriately and does not
accumulate any underimmunized time. By comparison, a
child who receives their first DTaP at 94 days of age has
accumulated 2 days of underimmunized time (i.e., under-
immunized for days 92 and 93, and up-to-date on day 94
for the first dose of DTaP).
Description of covariates
In addition to the PCV exposure cohorts, other vaccine
policy and temporal factors related to immunization cov-
Table 1: Variation in the expected number of vaccine injections 
during the first year of life, by provider group and PCV policy 
period
Number of vaccine injections expected during the first 
year of life
Group Pre-PCV birth cohort Post-PCV birth cohort
Group A† 7* or 10 10* or 13
Group B‡ 10 13
Group C§ 10 10* or 13
Group D|| 7* or 10 10* or 13
A child born during the pre-PCV period is expected to receive 3 DTP 
vaccinations, 2 polio vaccinations, 3 Hib vaccinations, and 2 hepatitis B 
vaccinations during the first year of life. Introduction of PCV added 
three new vaccine injections.
* Replacement of the separate hepatitis B and Hib vaccines during the 
first year of life with 2 doses of hepatitis B-Hib combination vaccine 
reduces the number of vaccine injections expected during the first 
year of life to 7 shots in the pre-PCV period and 10 in the post-PCV 
period.
† Hepatitis B-Hib combination vaccine available throughout the study 
period.
‡ Hepatitis B-Hib combination vaccine never available during the study 
period.
§ Hepatitis B-Hib combination vaccine available starting in 2000 
following PCV introduction, based on descriptive analyses.
|| Hepatitis B-Hib combination vaccine available starting in mid-1999 
prior to PCV introduction, based on descriptive analyses.BMC Pediatrics 2005, 5:43 http://www.biomedcentral.com/1471-2431/5/43
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erage were considered. Between July and September 1999,
providers were encouraged to delay initiation of hepatitis
B vaccination for low-risk infants from birth to 2–6
months of age because of safety concerns about thimero-
sal[12]. While resumption of hepatitis B birth vaccination
practices was recommended after regulatory approval of
the first thimerosal-free hepatitis B vaccine formulation in
September 1999,[13] reinstatement of universal birth vac-
cination policies occurred slowly [14-17]. Two indicators
were included in the regression models to account for
potential disruptions in immunization coverage during
the pre-PCV period, related the temporary hepatitis B
birth dose suspension ("HB delay" cohort: date of birth
between July – September 1999) and to incomplete
resumption of hepatitis B birth vaccination practices ("HB
carryover" cohort: date of birth between October 1999 –
January 2000).
Temporal trends in immunization coverage were modeled
using four variables based on birth month cohort: a linear
slope was fit for the entire study period, and three addi-
tional linear trends were included to estimate changes in
slope during the HB delay, HB carryover, and post-PCV
periods relative to the pre-PCV baseline trend.
An indicator variable was included to account for a poten-
tial change in the level of immunization coverage after
integration of PCV into routine practice ("PCV routine":
July – November 2000) compared to the initial PCV adop-
tion period ("PCV adoption": February – June 2000).
Selection of the July 2000 birth cohort as the transition
point after which PCV entered routine use was based on
descriptive analyses of the adoption of PCV in the partici-
pating provider groups.
Finally, seasonal variation in immunization scheduling
could affect the timeliness of vaccination and was entered
into the time spent underimmunized regression models
using indicator variables for calendar month of birth.
Figure 1 illustrates how the hepatitis B and PCV policy var-
iables are temporally related.
Statistical analysis
Logistic regression was used to assess the association
between PCV introduction and a child's probability of
being up-to-date at 13 months.
For the second outcome, time spent underimmunized, we
expected that the majority of children would be vacci-
nated age-appropriately (i.e., zero days spent underimmu-
nized by 13 months), and a two-part modelling
approach[18] was applied. First, a logistic regression
model was used to assess the association between PCV
introduction and a child's probability of having received
all vaccines age-appropriately by 13 months of age. Then,
among children who spent at least one day underimmu-
nized, negative binomial regression was used to evaluate
the impact of PCV introduction on the discrete outcome,
number of days spent underimmunized by 13 months.
Negative binomial regression accounts for overdispersion
in the data[19] and provides relative rate estimates for the
association between PCV introduction and the number of
days spent underimmunized.
Analyses were stratified by provider group because differ-
ences in baseline immunization coverage, differing con-
cern regarding multiple injections, and provider group-
specific decisions to use combination vaccines may have
differentially affected the impact of PCV introduction
across the provider groups. To allow comparisons across
sites, the set of variables included in the regression analy-
sis for each outcome was fixed across the provider groups.
Based on the regression model, we estimated the effect of
introduction of PCV at two points – (1) immediately fol-
lowing PCV introduction (February 2000 birth cohort)
and (2) after PCV was integrated into routine use (July
2000 birth cohort) – comparing each to the outcome as
predicted from the pre-PCV baseline trend. Comparison
of the PCV routine use period to the predicted baseline
trend was considered of primary interest because it meas-
ures the impact of addition of PCV, allowing for a period
of adjustment to the new PCV policy. Figure 2 illustrates
the calculation of these two contrasts for the up-to-date
outcome as an example. Given that the baseline propor-
tion of children who were up-to-date or who were vacci-
nated age-appropriately was expected to be high, under
these conditions, odds ratios should not be interpreted as
approximately the relative risk. Absolute differences in
coverage were also provided, comparing the probability
fitted from multivariate regression models based on the
observed data ("fitted probability") to the "predicted
probability" extrapolated from the baseline trend (e.g.,
absolute differenceFeb2000  = [fitted probability]Feb2000  -
[predicted probability]Feb2000). All analyses were per-
formed using SAS software, Version 8.2 of the SAS System
for Windows (SAS Institute, Cary, NC).
Results
Study population and adoption of PCV
In the four provider groups, 38,588 children met study
inclusion criteria. Due to the identification of a potential
disruption in the immunization tracking system during
the early part of the study period in one of the provider
groups, the study population for that site (Group D) was
additionally restricted to children born between Novem-
ber 1998 and November 2000. This resulted in a final
study population of 33,319 children.BMC Pediatrics 2005, 5:43 http://www.biomedcentral.com/1471-2431/5/43
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Following its introduction in February 2000, the rate of
adoption of PCV varied but was relatively rapid across the
four sites. Among children born in July 2000, over 85% of
children in each of three provider groups (Groups A, B,
and D) received PCV at their 2-month visit. In Group C,
while only 24% of the July 2000 birth cohort had received
PCV at a 2-month visit, 76% in the August 2000 cohort
had done so. Notwithstanding the age at which the PCV
series was initiated, between 92% (Group C) and 96%
(Group D) of the July 2000 birth cohort had received
three shots of PCV by 13 months.
Impact of PCV recommendations on probability of being 
up-to-date at 13 months
Overall, 93% of children were up-to-date at age 13
months. In each provider group, the percent of 13-month-
olds who were up-to-date either was maintained or
increased slightly from the pre-PCV to the post-PCV
cohorts (Figure 3).
In Group C, children born at the start of the PCV adoption
period were less likely to be up-to-date at 13 months com-
pared to the pre-PCV baseline after multivariate adjust-
ment for the HB delay and carryover periods (OR = 0.5,
95% CI: 0.4 – 0.8) (Table 2). This decrease persisted even
after PCV entered routine use (Group C: OR = 0.5, 95%
CI: 0.3 – 0.8), representing 3% fewer children in Group C
who were up-to-date compared to the predicted baseline
trend. Additional analyses indicated that children in
Group C were less likely to be up-to-date in the HB delay
(OR = 0.4; 95% CI: 0.3 – 0.6) and HB carryover (OR =
0.25; 95% CI: 0.17 – 0.35) periods compared to baseline,
preceding the introduction of PCV. This suggests that the
decrease observed in post-PCV period in Group C may
have been due to the lingering effects of the hepatitis B
birth dose suspension. In contrast, PCV introduction was
not significantly associated with a child's probability of
being up-to-date at 13 months in the three other provider
groups.
Impact of PCV recommendations on time spent 
underimmunized by 13 months
Overall, 70% of children received all non-PCV recom-
mended vaccinations without incurring any underimmu-
nized time. Among the 30% of children who were ever
delayed for at least one vaccination, a median of 122 days
(interquartile range: 33 – 212) was spent underimmu-
nized during the first 13 months of life.
Multivariate-adjusted results are provided only for Groups
A, B, and C because the truncated study period for Group
D limited our ability to fit the full multivariate model for
this population (Table 3). Children born at the start of the
PCV adoption period were less likely to receive all vacci-
nations without delay in Group B (OR = 0.4, 95% CI: 0.3–
0.5) and in Group C (OR = 0.33, 95% CI: 0.26 – 0.42).
These differences persisted through the start of the PCV
routine period (Group B OR = 0.4, 95% CI: 0.3 – 0.6;
Group C OR = 0.5, 95% CI: 0.4 – 0.7), representing 16%
(Group B) and 14% (Group C) fewer children among the
July 2000 birth cohort who spent no time underimmu-
nized compared to baseline. In Group A, no difference in
timeliness of immunization delivery was noted following
PCV introduction.
Timing of PCV introduction and hepatitis B policy periods Figure 1
Timing of PCV introduction and hepatitis B policy periods. "Pre-PCV" and "Post-PCV" describe the timing of the 
exposure birth cohorts. The "pre-PCV" cohort includes children born prior to introduction of pneumococcal conjugate vac-
cine (date of birth between October 1996 – January 2000) while the "post-PCV" cohort includes children born after introduc-
tion of pneumococcal conjugate vaccine to the end of the study period (date of birth between February – November 2000). 
"HB delay" refers to children born during the temporary hepatitis B birth dose suspension (July – September 1999). "HB carry-
over" refers to children born after reinstatement of hepatitis B birth vaccination recommendations and before introduction of 
pneumococcal conjugate vaccine (October 1999 – January 2000). "PCV adoption" represents the first five months following 
introduction of pneumococcal conjugate vaccine and the period of initial uptake of pneumococcal conjugate vaccine in the four 
study sites (date of birth between February – June 2000). "PCV routine" represents the five-month period after adoption of 
pneumococcal conjugate vaccine had occurred (date of birth between July – November 2000).
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Among children ever-delayed, children born during the
PCV adoption period in Group C spent 1.5 times as many
days underimmunized (CI: 1.3 – 1.8) compared to the
predicted baseline trend. This increase in days spent
underimmunized persisted among the PCV routine use
cohort compared to the baseline trend (RR: 1.4, 95% CI:
1.2 – 1.8), representing a delay of 103 days versus 73 days
on average, among children in Group C who were ever-
underimmunized. In contrast, no significant difference in
the number of days spent underimmunized was found in
the other two Groups, for either the PCV adoption cohort
(Group A RR: 1.1, 95% CI: 0.7–1.7; Group B RR: 1.1, 95%
CI: 0.8–1.4) or the PCV routine use cohort (Group A RR:
1.4, 95% CI: 0.8–2.2; Group B RR: 0.9; 95% CI: 0.6–1.2),
compared to the baseline trend.
Introduction of PCV and immunization coverage for 
individual vaccine series
Additional analyses suggest that the decrease in probabil-
ity of being up-to-date observed in Group C was not
driven by disruptions in one vaccine series alone. Chil-
dren in Group C were less likely to be up-to-date at the
start of the PCV adoption period for hepatitis B vaccina-
tion (OR = 0.4, 95% CI: 0.2 – 0.8) as well as for each of
the other vaccine series (polio: OR = 0.48, 95% CI: 0.24 –
0.96; DTP: OR = 0.65, 95% CI: 0.41 – 1.03; Hib: OR =
PCV introduction and immunization coverage: illustration of primary contrasts Figure 2
PCV introduction and immunization coverage: illustration of primary contrasts. Graph uses data from Group C as 
an example. ---: coverage based on multivariate regression models and the observed data. - - - -: coverage predicted from the 
pre-PCV baseline trend. Time point a: February 2000 birth cohort, start of the PCV adoption period. Contrast a compares 
immunization coverage for the February 2000 birth cohort based on the observed data to that predicted from the pre-PCV 
baseline trend. Time point b: July 2000 birth cohort, start of the PCV routine period. Contrast b compares immunization cov-
erage for the July 2000 birth cohort based on the observed data to that predicted from the pre-PCV baseline trend.
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0.60; 95% CI: 0.38 – 0.96). These effects persisted after
PCV entered routine use for the polio (OR = 0.48, 95% CI:
0.23–1.01), DTP (OR = 0.5, 95% CI: 0.3–0.9) and Hib
(OR = 0.5, 95% CI: 0.3–0.9) vaccine series compared to
baseline. In the three provider groups where PCV intro-
duction was not associated with changes in up-to-date
coverage among 13-month-olds, no systematic differ-
ences in coverage for individual vaccine series were
observed. Similar broader disruptions across individual
vaccine series were observed for the impact of PCV on the
time spent underimmunized by13 months (data not
shown).
Discussion
In our study of four large provider group populations, the
introduction of PCV was not associated with a substantial
adverse impact on a child's probability of being up-to-
date at 13 months for non-PCV recommended childhood
vaccines. We did find moderate increases in time spent
underimmunized in some provider groups, although
these delays likely did not result in clinical harm. Our
findings suggest that the timeliness of immunization for
several vaccine series was likely adversely affected by
either PCV introduction or the hepatitis B birth dose sus-
pension, although it was not possible to disentangle the
effects of these two policy changes. Overall, our findings
support continued vigilance during changes in immuniza-
tion policy in order to mitigate unintended delays in vac-
cine delivery that may arise due to concerns about
multiple injections.
Our finding of no major impact of PCV introduction on
up-to-date status is consistent with reports that increases
in the number of vaccine injections have not led to clini-
Percent up-to-date for non-PCV recommended vaccines at 13 months Figure 3
Percent up-to-date for non-PCV recommended vaccines at 13 months. Children were grouped by the month and 
year of their birth. Note: Data between April – October 1998 were considered incomplete in Group D due to a potential dis-
ruption in their immunization information system during the pre-PCV baseline period.
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cally important reductions in immunization cover-
age[11]. While providers and parents have expressed
concerns regarding multiple injections,[4,6,20,21] many
parents still prefer that all recommended vaccines be
given at one visit[20]. Recent surveys also suggest that pro-
viders are now more willing to administer multiple injec-
tions[7,21,22]. These findings are consistent with results
from the 2003 National Immunization Survey,[23] which
indicate that coverage levels for other childhood vaccines
among children aged 19–35 months of age had been
maintained during the adoption of PCV.
The heterogeneity in the response to PCV introduction
observed across the sites may have arisen due to a variety
of reasons. Responses to hepatitis B policy changes dif-
fered across the provider groups, and only those sites that
experienced disruptions during the hepatitis B delay and
carryover periods had lower immunization coverage fol-
lowing PCV introduction. If the effects of the hepatitis B
vaccination policy reversals lingered as PCV entered rou-
tine use in our health plan populations (i.e., 10 months
after reinstatement of the birth vaccination recommenda-
tions), our study would be unable to fully disentangle the
relative contributions of these two policies. Availability of
the hepatitis B-Hib combination vaccine may simplify
immunization scheduling by reducing the total number
of shots a child receives during the first year of life,[24]
and the differential adoption of the combination hepatitis
B-hib vaccine may have influenced the variation observed
across provider groups. The routine use of the combina-
tion hepatitis B-Hib vaccine in Group A throughout the
study period may have made immunization scheduling
less sensitive to the temporary hepatitis B birth dose sus-
pension or alleviated concerns about multiple injections
related to the introduction of PCV.
Implementation of the hepatitis B-Hib combination vac-
cine during the study period in Group C and Group D
may also have influenced the impact of PCV introduction
on immunization coverage in these settings; however, the
coincident timing of the implementation of the hepatitis
B-Hib combination vaccine with the temporary hepatitis
B birth dose suspension (Group D) and PCV adoption
(Group D) limits our ability to determine separate effects
for these policy changes in our analysis. We also com-
pared immunization coverage for non-PCV vaccinations
following PCV introduction with predictions of immuni-
zation coverage extrapolated from baseline trends.
Dependent on the level of baseline immunization cover-
age, expectation of a continued constant trend in immu-
Table 3: PCV introduction and probability of never being underimmunized by 13 months of age
Contrast a: PCV adoption vs. pre-PCV baseline Contrast b: PCV routine vs. pre-PCV baseline
Group Odds ratio 95% CI Fitted 
probability
Predicted 
probability
Odds ratio 95% CI Fitted 
probability
Predicted 
probability
Group A 1.1 0.7 – 1.6 0.83 0.82 1.1. 0.7 – 1.8 0.86 0.85
Group B 0.4 0.3 – 0.5 0.55 0.77 0.4 0.3 – 0.6 0.65 0.81
Group C 0.33 0.26 – 0.42 0.34 0.60 0.5 0.4 – 0.7 0.58 0.72
Contrast a compares a child's probability of spending zero days underimmunized by 13 months among the February 2000 birth cohort based on 
the observed data to that predicted from the pre-PCV baseline trend. Contrast b compares a child's probability of spending zero days 
underimmunized by 13 months among the July 2000 birth cohort based on the observed data to that predicted from the pre-PCV baseline trend. 
For each contrast, the "fitted probability" was the probability of spending no time underimmunized as fitted from the multivariate regression models 
and the "predicted probability" was extrapolated from the pre-PCV baseline trend.
Table 2: PCV introduction and probability of being up-to-date at 13 months
Contrast a: PCV adoption vs. predicted baseline Contrast b: PCV routine vs. predicted baseline
Group Odds ratio 95% CI Fitted 
probability
Predicted 
probability
Odds ratio 95% CI Fitted 
probability
Predicted 
probability
Group A 1.0 0.5 – 1.8 0.95 0.95 0.8 0.4 – 1.4 0.94 0.95
Group B 0.5 0.2 – 1.2 0.96 0.98 0.7 0.3 – 1.5 0.97 0.98
Group C 0.5 0.4 – 0.8 0.92 0.95 0.5 0.3 – 0.8 0.93 0.96
Group D 1.2 0.5 – 2.9 0.90 0.89 2.0 0.6 – 7.0 0.94 0.88
Contrast a compares a child's probability of being up-to-date at 13 months among the February 2000 birth cohort to that predicted from the pre-
PCV baseline trend. Contrast b compares a child's probability of being up-to-date at 13 months among the July 2000 birth cohort to that predicted 
from the pre-PCV baseline trend. For each contrast, the "fitted probability" was the probability of being up-to-date as fitted from the multivariate 
regression models based on the observed data and the "predicted probability" was extrapolated from the pre-PCV baseline trend.BMC Pediatrics 2005, 5:43 http://www.biomedcentral.com/1471-2431/5/43
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nization coverage may have yielded an overestimate of the
extent of disruption in immunization coverage in some
settings. It is reassuring that PCV introduction was not
associated with clinically important reductions in immu-
nization coverage, even given expectations of a linear
trend predicted from baseline. Finally, flexibility in
immunization guidelines or expectations regarding the
simultaneous administration of vaccines may vary across
sites and influence variation in immunization scheduling.
This study evaluates the impact of introduction of the PCV
policy and not whether administration of PCV to a given
child affects that individual's probability of being up-to-
date. Given the rapid adoption of PCV in the four provider
groups, we are able to estimate the net effect of integration
of PCV into the childhood immunization schedule. Infor-
mation on certain demographic factors (e.g., race/ethnic-
ity, socioeconomic status) was not routinely collected
across these settings, and we were unable to directly assess
the effects of these characteristics in the analysis. How-
ever, by comparing birth cohorts across the study period,
only those characteristics whose distribution in the study
population changed concurrently with the time of intro-
duction of PCV can act as potential confounders. No
major changes in the coverage plans offered by these
health plans occurred at the time of PCV introduction,
and we therefore would not expect the demographic char-
acteristics of the enrolled populations in these provider
groups to have changed dramatically concurrent with
introduction of the new PCV policy.
Finally, this study was conducted in health plan popula-
tions, who are mostly privately insured and have good
access to health care. The study population was addition-
ally restricted to children who were continuously enrolled
during the first year of life; these children are likely to have
experienced less scattering of their immunization records
and to have had more opportunities to catch-up on
immunizations. While children in the study population
are thus likely to have higher overall immunization cover-
age than might be expected for the general population,
comparison across similarly restricted birth cohorts
remains valid to evaluate the potential impact of the intro-
duction of PCV. In addition, earlier evaluations of the
impact of the transition from oral polio vaccine to inacti-
vated (injected) polio vaccine have yielded similar find-
ings of a lack of an adverse effect on immunization
coverage among children enrolled in managed care popu-
lations[11] and among children receiving vaccinations in
public clinics[20].
Conclusion
The continued development and addition of new vaccines
to the childhood immunization schedule is likely to exac-
erbate concerns regarding simultaneous multiple injec-
tions. Our findings indicate that these provider groups
remained capable of absorbing the most recent increases
in multiple injections with minimal impact on up-to-date
measures. However, the timeliness of delivery may have
been affected by the introduction of PCV and the suspen-
sion of the birth dose of hepatitis B vaccine. This study
highlights the continuing need to monitor the impact of
new vaccines as well as vaccine-safety related policy deci-
sions that affect immunization scheduling.
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